Actively Recruiting
Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II
Led by Universität Münster · Updated on 2025-07-18
1022
Participants Needed
4
Research Sites
104 weeks
Total Duration
On this page
Sponsors
U
Universität Münster
Lead Sponsor
G
German Research Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.
CONDITIONS
Official Title
Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older
- Undergoing cardiac surgery using cardiopulmonary bypass including coronary artery bypass grafting (CABG), valve surgery, or combined CABG/valve surgery
- Elevated risk of acute kidney injury (AKI) predicted by a score of 1.5 or higher based on hemoglobin, creatinine, age, NYHA class, and BMI
- Provided written informed consent
You will not qualify if you...
- Major aortic surgery, transplant surgery, pulmonary thrombendarterectomy, or ventricular assist device placement
- Receiving inotropic or vasopressor support before surgery
- Dialysis dependent
- Pre-existing acute kidney injury within the last 30 days
- Chronic kidney injury with estimated glomerular filtration rate (eGFR) below 20 ml/min/1.73m2
- Significant hypertension with persistent systolic blood pressure over 180 mmHg
- Significant pulmonary hypertension with right ventricular dysfunction worse than mild
- Allergy to study drugs or their components
- Pregnant or breastfeeding women
- Dependency on the investigator or employment by the sponsor/investigator
- Participation in another interventional trial affecting kidney function within the last three months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Deutsches Herzzentrum der Charité
Berlin, Germany, 13353
Actively Recruiting
2
University Hospital Bonn
Bonn, Germany, 53127
Actively Recruiting
3
University Medical Center Mainz
Mainz, Germany, 55131
Actively Recruiting
4
University Hospital Münster
Münster, Germany, 49149
Actively Recruiting
Research Team
A
Alexander Zarbock, MD
CONTACT
M
Melanie Meersch-Dini, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here